Hereditary Angioedema Clinical Trial
Official title:
A Single Sequence, Open-Label Drug-Drug Interaction Study to Evaluate the Effect of BCX7353 on Cytochrome P450 3A4, 2C9, 2C19 and 2D6 Enzyme Activity Using Probe Substrates in Healthy Subjects
Verified date | June 2016 |
Source | BioCryst Pharmaceuticals |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is an open-label, single sequence study to evaluate the effect of BCX7353 on hepatic and intestinal cytochrome P450 enzymes using probe substrate drugs in healthy subjects. Pharmacokinetics of the probe substrate drugs will be measured prior to and following administration of multiple doses of BCX7353.
Status | Completed |
Enrollment | 20 |
Est. completion date | June 2016 |
Est. primary completion date | June 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 55 Years |
Eligibility |
Key Inclusion Criteria: - Written informed consent - Body mass index 18 to 32 kg/m2 - Abides by study restrictions - Attends all study visits and agrees to remain in study center for the confinement period - Acceptable birth control measures for male subjects and women of childbearing potential Key Exclusion Criteria: - Clinically significant medical history, current medical or psychiatric condition. This includes a history of clinically significant gastrointestinal, hematologic, renal, hepatic, bronchopulmonary, neurological, or cardiac disease - Clinically significant ECG finding, vital sign measurement or laboratory/urinalysis abnormality at screening or baseline - Poor or ultra- metabolizers of CYP2C19 or CYP2D6 Use of over the counter or prescription medication within 14 days of dosing and anticipated use through the follow-up visit - Use of medication or consumption of any substance that is known to inhibit or induce metabolic enzymes or transporters within 30 days of dosing - Participation in any other investigational drug study within 90 days of screening - Recent or current history of alcohol or drug abuse - Regular recent use of tobacco or nicotine products - Positive serology for HBV, HCV, or HIV - Pregnant or nursing - Donation or loss of greater than 400 mL of blood within 3 months - Serious adverse reaction or serious hypersensitivity to any drug |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Quotient Clinical Ltd | Ruddington | Nottingham |
Lead Sponsor | Collaborator |
---|---|
BioCryst Pharmaceuticals |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cmax of probe substrates | plasma pharmacokinetic parameters are based on blood sampling through 24 hours on Day 1, 2, 10 and 11 | ||
Primary | Tmax of probe substrates | plasma pharmacokinetic parameters are based on blood sampling through 24 hours on Day 1, 2, 10 and 11 | ||
Primary | AUClast of probe substrates | plasma pharmacokinetic parameters are based on blood sampling through 24 hours on Day 1, 2, 10 and 11 | ||
Primary | AUCinf of probe substrates | plasma pharmacokinetic parameters are based on blood sampling through 24 hours on Day 1, 2, 10 and 11 | ||
Primary | t1/2 of probe substrates | plasma pharmacokinetic parameters are based on blood sampling through 24 hours on Day 1, 2, 10 and 11 | ||
Primary | Cl of intravenous midazolam | plasma pharmacokinetic parameters are based on blood sampling through 24 hours on Day 1, 2, 10 and 11 | ||
Secondary | adverse events | absolute and change from baseline through study day 11 | ||
Secondary | laboratory analyses | absolute and change from baseline through study day 11 | ||
Secondary | Vital signs | absolute and change from baseline through study day 11 | ||
Secondary | physical examination findings | absolute and change from baseline through study day 11 | ||
Secondary | electrocardiograms | absolute and change from baseline through study day 11 | ||
Secondary | C24 for tolbutamide | plasma pharmacokinetic parameters are based on blood sampling through 24 hours on Day 1, 2, 10 and 11 | ||
Secondary | C6 for IV and oral midazolam | plasma pharmacokinetic parameters are based on blood sampling through 24 hours on Day 1, 2, 10 and 11 | ||
Secondary | Probe/metabolite AUC24 ratio | plasma pharmacokinetic parameters are based on blood sampling through 24 hours on Day 1, 2, 10 and 11 | ||
Secondary | Tlag of probe substrates | plasma pharmacokinetic parameters are based on blood sampling through 24 hours on Day 1, 2, 10 and 11 | ||
Secondary | VdF of probe substrates | plasma pharmacokinetic parameters are based on blood sampling through 24 hours on Day 1, 2, 10 and 11 | ||
Secondary | CL/F of oral probe substrates | plasma pharmacokinetic parameters are based on blood sampling through 24 hours on Day 1, 2, 10 and 11 | ||
Secondary | Vss of intravenous midazolam | plasma pharmacokinetic parameters are based on blood sampling through 24 hours on Day 1, 2, 10 and 11 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT06007677 -
A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema
|
Phase 2 | |
Completed |
NCT00997204 -
EASSI - Evaluation of the Safety of Self-Administration With Icatibant
|
Phase 3 | |
Completed |
NCT00438815 -
Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks
|
Phase 3 | |
Completed |
NCT00748202 -
Berinert P Study of Subcutaneous Versus Intravenous Administration
|
Phase 3 | |
Completed |
NCT01426763 -
A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration of CINRYZE With Recombinant Human Hyaluronidase
|
Phase 2 | |
Terminated |
NCT04091113 -
Hereditary Angioedema Kininogen Assay
|
||
Completed |
NCT00432510 -
Pharmacokinetics of C1 Esterase Inhibitor in Hereditary Angioedema Subjects
|
Phase 1 | |
Completed |
NCT03712228 -
A Study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE)
|
Phase 2 | |
Active, not recruiting |
NCT05453968 -
Berotralstat Treatment in Children With Hereditary Angioedema
|
Phase 3 | |
Recruiting |
NCT05511922 -
PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial
|
Phase 3 | |
Recruiting |
NCT05505916 -
An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)
|
Phase 3 | |
Not yet recruiting |
NCT02159430 -
Hereditary AngioEdema, Neurobiology and Psychopathology
|
N/A | |
Completed |
NCT02303626 -
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
|
Phase 2/Phase 3 | |
Completed |
NCT01984788 -
Safety and Efficacy of Oral BCX4161 as a Prophylactic Treatment for HAE
|
Phase 2 | |
Completed |
NCT04888650 -
Assessment of the State of Health, Quality of Life and Expectations of Patients With Hereditary Angioedema
|
||
Completed |
NCT02448264 -
First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BCX7353 in Healthy Western and Japanese Volunteers
|
Phase 1 | |
Completed |
NCT05118958 -
Phase 1 Crossover Study in Healthy Subjects to Evaluate the PK Profile of KVD824 Following Single and Multiple Doses of Modified Release (MR) Formulations
|
Phase 1 | |
Completed |
NCT06414252 -
Social Evaluated Cold Pressor Test in Hereditary Angioedema Patients
|
||
Active, not recruiting |
NCT04739059 -
Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks
|
Phase 3 | |
Completed |
NCT01679912 -
A Call Center During HAE Attacks (SOS HAE)
|
Phase 4 |